# Cold and Flu Drugs Market

> Cold and Flu Drugs Market Research Report Information By Type (Antihistamines, Expectorants, Bronchodilators, Decongestants, and Others), By Application (Over the Counter (OTC), and Rx. Over the Counter (OTC)), and By Region (North America, Europe, Asia-Pacific, and Rest of the World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.5%
- **2024:** $ 17.57 Billion
- **2025:** $ 18.88 Billion
- **2035:** $ 38.92 Billion
- **Key Players:** Pfizer (US), Johnson & Johnson (US), GlaxoSmithKline (GB), Bayer (DE), Sanofi (FR), Novartis (CH), AbbVie (US), Mylan (US), Roche (CH)

**Report ID:** MRFR/Pharma/20106-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/cold-and-flu-drugs-market-21704

---

## Market Summary

## **Cold and Flu Drugs Market Overview**

Cold and Flu Drugs Market Size was valued at USD 15.2 Billion in 2022. The Cold and Flu Drugs market industry is projected to grow from USD 16.34 Billion in 2023 to USD 29.14 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2023 - 2032). Increasing public awareness of seasonal illnesses and increased healthcare costs are the key market drivers accelerating market expansion.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cold and Flu Drugs Market Trends**

Market CAGR for cold and flu drugs is being driven by the rising awareness about health enhancing supplements. Most commonly, cold and flu supplements serve as immune boosters for people. Patients prefer cold and flu supplements over medications because of their natural qualities. The supplements help to strengthen immunity against the flu, the common cold, and other illnesses because they are natural concoctions produced from herbal extracts. Numerous over-the-counter cold and flu supplements, such as vitamin C, elderberry supplements, ginseng supplements, and garlic preparations, are offered in the market.

Additionally, changes in lifestyles and better access to supplements through offline and online merchants have fueled the demand for cold and flu supplements around the world. Consumers' growing understanding of the therapeutic benefits of several natural substances is also fueling the market for Cold and Flu supplements and over-the-counter (OTC) medications. Additionally, growing consumer spending is projected on a range of immune health products, such as Cold and Flu supplements. Customers have been requesting more Cold And Flu vitamins in order to boost immunity and prevent the spread of these ailments.

The main goal of cold and flu supplements is to strengthen the immune system of the user.

A rise in financial resources and population is another factor influencing market expansion. As more public and private organizations focus their research and development efforts on creating drug delivery systems and effective medications that can be bought at the neighborhood pharmacy, medical supply store, or online, the potential for the cold and flu drugs market to grow is likely to rise. The market's progress may be hindered by restrictions such a lack of awareness of active drugs in underdeveloped and rural areas.

Drug addiction and the risk for adverse drug reactions are the key factors preventing the Cold and Flu industry from growing.

For instance, the CDC estimates that the common cold prevents 22 million American students from attending class each year. In addition, the number of cold cases in the US each year is close to 1 billion. Thus, result in driving the Cold and Flu Drugs market revenue.

## **Cold and Flu Drugs Market Segment Insights**

### **Cold and Flu Drugs Type Insights**

The Cold and Flu Drugs market segmentation, based on type includes Antihistamines, Expectorants, Bronchodilators, Decongestants, and Others. The antihistamines segment dominated the market. The symptoms of allergies or colds, such as itchiness, sneezing, and runny noses, are usually treated with antihistamines. They work by lessening the effects of histamine, which is a substance the body produces in response to an allergic reaction. Antihistamines are widely available without a prescription and come in a range of dose forms, including as pills, liquids, and nasal sprays.

### **Cold and Flu Drugs Application Insights**

The Cold and Flu Drugs market segmentation, based on Application, includes Over the Counter (OTC), and Rx. Over the Counter (OTC). The over the counter (OTC ) category generated the most income. This is because the prevalence of the common cold, the flu, and digestive problems is increasing. OTC drugs are pharmaceuticals that can be obtained by consumers without a prescription from a doctor. They are also known as non-prescription drugs.

**Figure1:  Cold and Flu Drugs Market, by Application, 2022&2032 (USD Billion)**

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Cold and Flu Drugs Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Cold and Flu Drugs market area will dominate this market. This is due to a greater emphasis being placed on keeping a healthy diet and lifestyle as North Americans embrace health consciousness.

Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

**Figure2:  COLD AND FLU DRUGS MARKET SHARE BY REGION 2022 (USD Billion)**

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

Europe Cold and Flu Drugs market represents the second-largest market share. Growing demand for such supplements is influenced by shifting parental choices for preventative healthcare and a pro-active approach to sickness management. Further, the German Cold and Flu Drugs market held a dominant market share, and the UK Cold and Flu Drugs market was the European region's fastest-growing market.

The Asia-Pacific Cold and Flu Drugs Market is anticipated to see the fastest CAGR between 2023 and 2032. This is because of things like a dense population, urbanization, and more viral exposure. Moreover, China’s Cold and Flu Drugs market held a dominant market share, and the Indian Cold and Flu Drugs market was the Asia-Pacific region's fastest-growing market.

**Cold and Flu Drugs Key Market Players& Competitive Insights**

Leading market players are putting a lot of money on R&D to broaden the range of their goods, which will help the market for Cold and Flu Drugs grow even more. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other organizations. to grow and endure in an increasingly competitive and challenging market environment, Cold and Flu Drugs industry must provide reasonably priced goods.

One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the  Cold and Flu Drugs industry to develop market sector and provide benefits to customers. In recent years, the Cold and Flu Drugs industry has provided some of medicine's greatest important benefits. Major players in the Cold and Flu Drugs market, including F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, GSK plc, Lilly, Merck & Co., Inc., Novartis AG, and others, invest in operations for research and development in an effort to improve market demand.

Roche is the brand name for F. Hoffmann-La Roche AG, a multinational healthcare conglomerate with the diagnostics and pharmaceuticals sectors. The holding company, Roche Holding AG, trades its shares on the SIX Swiss Exchange. The corporate headquarters are located in Basel. The leading provider of cancer medications in the world and the fifth-largest pharmaceutical company in terms of sales is Roche. 

The business owns a totally owned affiliate of the American biotechnology corporation Genentech, as well as the Japanese biotechnology company Chugai Pharmaceuticals and the American businesses Ventana and Foundation Medicine. In 2020, With the FDA's clearance of its high-volume Sars-CoV-2 diagnostic test, which can analyze 1,400–8,800 samples in 24 hours using the exclusive Cobas 6800/8800 molecular testing system, the Roche Diagnostics division achieved a key milestone.

The Bristol-Myers Squibb Company, also known as Bristol Myers Squibb (BMS), is a  pharmaceutical company with its headquarters in the United States. One of the biggest pharmaceutical firms in the world, BMS is headquartered in Princeton, New Jersey, and it often appears on the Fortune 500 list of the biggest American enterprises. It generated $46.2 billion in total revenue for the fiscal year 2022. Bristol Myers Squibb produces prescription medications and biologics for the following therapeutic categories: cancer, HIV/AIDS, cardiovascular disease, diabetes, liver disease, rheumatoid arthritis (RA), and psychiatric disorders.

In 2022, BMS announced that it would buy Turning Point Therapeutics Inc. for a total of $4.1 billion in currency ($76 per share, a 122.5% premium to its most recent closing price), expanding its line-up of cancer medications to include repotrectinib.

**Key Companies in the Cold and Flu Drugs market include**

**Cold and Flu Drugs Industry Developments**

**March 2021:** Roche stated that it would pay $1.8 billion to purchase GenMark Diagnostics. According to the terms of the contract, Genmark Diagnostics will become a subsidiary and keep its core activities in Carlsbad, California.

**September 2023: **BMS disclosed that as part of a strategic license and partnership to create and market obexelimab, a brand-new, bi-functional antibody for autoimmune disorders, it will pay Zenas BioPharma $50 million up front.

**May 2022**: Nature's Way Products, LLC, announced a significant expansion of its Green Bay, Wisconsin, Gummy factory. Incorporating production, packaging, and warehouse space, the development will increase the present 80,000 square feet by 116,000 square feet. Early summer was the planned start date, and the project should be finished by the end of the third quarter of 2023.

## **Cold and Flu Drugs Market Segmentation**

### **Cold and Flu Drugs Type Outlook**

### **Cold and Flu Drugs Application Outlook**

### **Cold and Flu Drugs Regional Outlook**

## Market Drivers

### Rising Self-Medication Trends

The trend towards self-medication is becoming increasingly pronounced, influencing the Cold and Flu Drugs Market significantly. Consumers are increasingly opting for over-the-counter medications to manage their symptoms without the need for a prescription. This shift is driven by a growing awareness of available products and the convenience they offer. Market data suggests that self-medication can lead to a more proactive approach to health, with individuals seeking immediate relief from cold and flu symptoms. As a result, the Cold and Flu Drugs Market is likely to benefit from this trend, as more consumers turn to readily available medications. This behavior may also encourage pharmaceutical companies to innovate and diversify their product offerings to meet the evolving needs of self-medicating consumers.

### Expansion of E-commerce Platforms

The expansion of e-commerce platforms is transforming the Cold and Flu Drugs Market by providing consumers with greater access to a wide range of products. Online shopping has become increasingly popular, allowing individuals to purchase cold and flu medications conveniently from their homes. This trend is particularly relevant in regions where access to physical pharmacies may be limited. Market data suggests that e-commerce sales of over-the-counter medications are on the rise, driven by the convenience and competitive pricing offered by online retailers. As more consumers turn to digital platforms for their healthcare needs, the Cold and Flu Drugs Market is likely to see a significant shift in purchasing behavior, necessitating adaptations from traditional retailers.

### Increase in Respiratory Infections

The prevalence of respiratory infections, particularly during seasonal changes, appears to be a primary driver for the Cold and Flu Drugs Market. Data indicates that respiratory infections account for a substantial portion of healthcare visits, with millions affected annually. This surge in infections necessitates the availability of effective cold and flu medications, thereby propelling market growth. The Cold and Flu Drugs Market is likely to experience heightened demand during peak seasons, as consumers seek relief from symptoms. Furthermore, the increasing awareness of the importance of treating these infections promptly may lead to a rise in over-the-counter drug sales, further stimulating market dynamics. As healthcare systems continue to address these infections, the Cold and Flu Drugs Market is poised for sustained expansion.

### Increased Health Awareness and Education

The growing emphasis on health awareness and education is significantly impacting the Cold and Flu Drugs Market. As consumers become more informed about the symptoms and treatment options for cold and flu, they are more likely to seek appropriate medications. Public health campaigns and educational initiatives are contributing to this trend, encouraging individuals to recognize the importance of timely treatment. Consequently, the Cold and Flu Drugs Market is experiencing a shift towards more informed purchasing decisions, with consumers actively seeking effective remedies. This heightened awareness may also lead to increased demand for preventive measures, such as vaccines and supplements, further influencing market dynamics.

### Technological Advancements in Drug Development

Technological advancements in drug development are playing a crucial role in shaping the Cold and Flu Drugs Market. Innovations in formulation techniques and delivery systems are enhancing the efficacy and safety profiles of cold and flu medications. For instance, the introduction of novel drug delivery methods, such as nanotechnology, is enabling more targeted and effective treatments. Market analysis indicates that these advancements not only improve patient outcomes but also drive consumer confidence in over-the-counter products. As pharmaceutical companies invest in research and development, the Cold and Flu Drugs Market is likely to witness a surge in new product launches, catering to diverse consumer needs and preferences.

## Future Outlook

The Cold and Flu Drugs Market is projected to grow at a 7.5% CAGR from 2025 to 2035, driven by increasing consumer awareness and advancements in drug formulations.

**New opportunities:**

- Development of personalized cold and flu medications
- Expansion of telehealth services for remote consultations
- Investment in AI-driven drug discovery platforms

By 2035, the market is expected to be robust, reflecting significant advancements and consumer engagement.

## Segment Insights

### By Type: Antihistamines (Largest) vs. Decongestants (Fastest-Growing)

In the Cold and Flu Drugs Market, the type segment features diverse products that cater to varying symptoms. Antihistamines take the lead, capturing the majority of market share due to their effectiveness in alleviating allergic responses related to cold symptoms. Following closely are decongestants, which have garnered significant attention for their role in relieving nasal congestion, establishing a robust presence as a user-favorite across demographics. Other valuable players such as expectorants, bronchodilators, and others contribute to the overall equilibrium of the market without overshadowing the leaders.

Antihistamines (Dominant) vs. Expectorants (Emerging)

Antihistamines are characterized by their long-standing dominance in the Cold and Flu Drugs Market, thanks to their dual capability of providing relief from cold symptoms and allergies. The preference for antihistamines stems from their wide availability and strong track record in mitigating symptoms such as runny noses and sneezing. On the other hand, expectorants are emerging in popularity, primarily due to growing awareness regarding productive cough alleviation. As more consumers lean towards natural and effective ways to manage symptoms, expectorants are expected to cultivate a dedicated user base, albeit their current status as secondary options in the market.

### By Application: Over the Counter (OTC) (Largest) vs. Rx (Fastest-Growing)

In the Cold and Flu Drugs Market, the Over the Counter (OTC) segment holds the largest market share, primarily due to its accessibility and wide consumer acceptance. Consumers favor OTC drugs for their convenience and effectiveness in relieving symptoms without requiring a prescription. This has led to substantial sales growth, particularly in the self-medication trend observed over recent years, as individuals increasingly prefer to treat mild symptoms without medical consultations.

On the other hand, the Prescription (Rx) segment is noted as the fastest-growing area within the market. The increased prevalence of cold and flu viruses and the growing focus on personalized medicine significantly drive the demand for Rx cold and flu treatments. Advances in medical research and a better understanding of the appropriate pharmacological approaches for severe cases are further fueling this segment's growth, thereby positioning it as a pivotal area for future market expansion.

Over the Counter (OTC) (Dominant) vs. Rx (Emerging)

The Over the Counter (OTC) segment stands as the dominant force in the Cold and Flu Drugs Market, characterized by its robust availability across pharmacies, supermarkets, and online platforms. This segment encompasses a wide array of products designed to alleviate various symptoms, catering to a broad consumer base. OTC products not only empower consumers to quickly address their health needs but also enjoy strong brand loyalty. In contrast, the Rx segment is emerging due to its focus on targeted therapies for more severe symptoms. While generally requiring a doctor's prescription, these products are gaining traction among healthcare professionals for their efficacy in treating complex cases of colds and flu, appealing particularly to patients seeking advanced treatment options.

## Regional Market Share Analysis

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Cold and Flu Drugs Market area will dominate this market. This is due to a greater emphasis being placed on keeping a healthy diet and lifestyle as North Americans embrace health consciousness.

Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

**Figure2:  COLD AND FLU DRUGS MARKET SHARE BY REGION 2022 (USD Billion)**

Europe Cold and Flu Drugs Market represents the second-largest market share. Growing demand for such supplements is influenced by shifting parental choices for preventative healthcare and a pro-active approach to sickness management. Further, the German Cold and Flu Drugs Market held a dominant market share, and the UK Cold and Flu Drugs Market was the European region's fastest-growing market.

The Asia-Pacific Cold and Flu Drugs Market is anticipated to see the fastest CAGR between 2023 and 2032. This is because of things like a dense population, urbanization, and more viral exposure. Moreover, China’s Cold and Flu Drugs Market held a dominant market share, and the Indian Cold and Flu Drugs Market was the Asia-Pacific region's fastest-growing market.

## Competitive Benchmarking

Leading market players are putting a lot of money on R&D to broaden the range of their goods, which will help the market for Cold and Flu Drugs Market grow even more. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other organizations. to grow and endure in an increasingly competitive and challenging market environment, Cold and Flu Drugs industry must provide reasonably priced goods.One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the  Cold and Flu Drugs industry to develop market sector and provide benefits to customers. In recent years, the Cold and Flu Drugs industry has provided some of medicine's greatest important benefits. Major players in the Cold and Flu Drugs Market, including F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, GSK plc, Lilly, Merck & Co., Inc., Novartis AG, and others, invest in operations for research and development in an effort to improve market demand.Roche is the brand name for F. Hoffmann-La Roche AG, a multinational healthcare conglomerate with the diagnostics and pharmaceuticals sectors. The holding company, Roche Holding AG, trades its shares on the SIX Swiss Exchange. The corporate headquarters are located in Basel. The leading provider of cancer medications in the world and the fifth-largest pharmaceutical company in terms of sales is Roche. The business owns a totally owned affiliate of the American biotechnology corporation Genentech, as well as the Japanese biotechnology company Chugai Pharmaceuticals and the American businesses Ventana and Foundation Medicine. In 2020, With the FDA's clearance of its high-volume Sars-CoV-2 diagnostic test, which can analyze 1,400–8,800 samples in 24 hours using the exclusive Cobas 6800/8800 molecular testing system, the Roche Diagnostics division achieved a key milestone.The Bristol-Myers Squibb Company, also known as Bristol Myers Squibb (BMS), is a  pharmaceutical company with its headquarters in the United States. One of the biggest pharmaceutical firms in the world, BMS is headquartered in Princeton, New Jersey, and it often appears on the Fortune 500 list of the biggest American enterprises. It generated $46.2 billion in total revenue for the fiscal year 2022. Bristol Myers Squibb produces prescription medications and biologics for the following therapeutic categories: cancer, HIV/AIDS, cardiovascular disease, diabetes, liver disease, rheumatoid arthritis (RA), and psychiatric disorders.In 2022, BMS announced that it would buy Turning Point Therapeutics Inc. for a total of $4.1 billion in currency ($76 per share, a 122.5% premium to its most recent closing price), expanding its line-up of cancer medications to include repotrectinib.

## Recent News & Developments

**March 2021:** Roche stated that it would pay $1.8 billion to purchase GenMark Diagnostics. According to the terms of the contract, Genmark Diagnostics will become a subsidiary and keep its core activities in Carlsbad, California.

**September 2023: **BMS disclosed that as part of a strategic license and partnership to create and market obexelimab, a brand-new, bi-functional antibody for autoimmune disorders, it will pay Zenas BioPharma $50 million up front.

**May 2022**: Nature's Way Products, LLC, announced a significant expansion of its Green Bay, Wisconsin, Gummy factory. Incorporating production, packaging, and warehouse space, the development will increase the present 80,000 square feet by 116,000 square feet. Early summer was the planned start date, and the project should be finished by the end of the third quarter of 2023.

## Report Scope

| MARKET SIZE 2024 | 17.57(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 18.88(USD Billion) |
| MARKET SIZE 2035 | 38.92(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Pfizer (US), Johnson & Johnson (US), GlaxoSmithKline (GB), Bayer (DE), Sanofi (FR), Novartis (CH), AbbVie (US), Mylan (US), Roche (CH) |
| Segments Covered | Type, Application, Region |
| Key Market Opportunities | Emergence of innovative formulations addressing consumer demand for rapid relief in the Cold and Flu Drugs Market. |
| Key Market Dynamics | Rising consumer demand for over-the-counter cold and flu medications drives innovation and competitive dynamics in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Cold and Flu Drugs Market?**
A: As of 2024, the Cold and Flu Drugs Market was valued at 17.57 USD Billion.

**Q: What is the projected market valuation for the Cold and Flu Drugs Market in 2035?**
A: The market is projected to reach a valuation of 38.92 USD Billion by 2035.

**Q: What is the expected CAGR for the Cold and Flu Drugs Market during the forecast period?**
A: The expected CAGR for the Cold and Flu Drugs Market from 2025 to 2035 is 7.5%.

**Q: Which companies are the key players in the Cold and Flu Drugs Market?**
A: Key players in the market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Sanofi, Novartis, AbbVie, Mylan, and Roche.

**Q: What are the main segments of the Cold and Flu Drugs Market?**
A: The main segments include Antihistamines, Expectorants, Bronchodilators, Decongestants, and Others.

**Q: How much is the Antihistamines segment projected to grow by 2035?**
A: The Antihistamines segment is projected to grow from 3.0 USD Billion in 2024 to 7.0 USD Billion by 2035.

**Q: What is the projected growth for Over the Counter (OTC) applications in the market?**
A: The Over the Counter (OTC) applications are expected to increase from 10.0 USD Billion in 2024 to 22.0 USD Billion by 2035.

**Q: What is the expected growth for Decongestants in the Cold and Flu Drugs Market?**
A: The Decongestants segment is anticipated to grow from 4.0 USD Billion in 2024 to 9.0 USD Billion by 2035.

**Q: How does the Rx application segment compare to OTC in terms of growth?**
A: The Rx application segment is projected to grow from 7.57 USD Billion in 2024 to 16.92 USD Billion by 2035, indicating substantial growth but less than OTC.

**Q: What does the market data suggest about the future of Cold and Flu Drugs?**
A: The data suggests a robust growth trajectory for the Cold and Flu Drugs Market, driven by increasing demand and innovation in drug formulations.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cold-and-flu-drugs-market-21704*